
Billiontoone Inc (BLLN) Stock Forecast & Price Target
Billiontoone Inc (BLLN) Analyst Ratings
Bulls say
BillionToOne is a molecular diagnostics company with a strong presence in the prenatal and oncology testing markets. Their QCT platform and conservative decision-making culture give them a competitive edge. With accretive contracts and favorable payment rates from private payors, the company is expected to continue its strong growth and profitability, despite potential risks from PAMA implementation. Partnerships and new tests, like the Unity Confirm fetal cell assay, are expected to drive further expansion.
Bears say
BillionToOne is facing significant risks including limitations in the growth of the prenatal market, competition in the therapy selection market, and potential limitations of its technology platform in highly competitive pipeline markets. Additionally, while the company has raised its revenue guidance for 2026, it has not included potential future limitations in its projections. Finally, the recent announcement of the upcoming launch of UNITY Confirm may provide a market share increase opportunity but may not significantly impact the company's overall revenue.
This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares